Peptide-Drug Conjugates (PDC): Targeted Delivery Platform, Linker Chemistry, and Clinical Pipeline 2026

Industry Authority | 2026-07-10 | 14 min read

A 2026 industry review of peptide-drug conjugates (PDCs): targeting ligand design (RGD, NGR, TAT, GLP-1), cleavable vs. non-cleavable linkers, payload chemistry (DM1, MMAE, camptothecin), and clinical pipeline analysis.

Introduction: the rise of peptide-drug conjugates

Antibody-drug conjugates (ADCs) transformed oncology — Kadcyla, Adcetris, Enhertu are now standard of care. But ADCs have limitations: high molecular weight (150 kDa), poor tumor penetration, expensive manufacturing, and immune-related adverse events.

Peptide-drug conjugates (PDCs) offer an alternative:

• **Smaller size**: 2-5 kDa vs. 150 kDa for ADCs
• **Better tumor penetration**: PDCs diffuse through tumor interstitium more efficiently
• **Lower cost**: peptide synthesis is cheaper than antibody production
• **Lower immunogenicity**: short peptides are less immunogenic than full antibodies
• **Easier manufacturing**: SPPS-based synthesis with well-established chemistry

This 2026 review covers PDC components, linker chemistry, clinical pipeline, and research applications.

PDC architecture

A PDC has three modular components:

1. Targeting peptide (homing ligand)

The peptide selects the target tissue or cell. Common targets:

| Target | Peptide | Sequence | Application | | --- | --- | --- | --- | | αvβ3 integrin | RGD | cyclo(RGDfK) | Tumor angiogenesis | | CD13 (APN) | NGR | cyclo(CNGRC) | Tumor vasculature | | Neuropilin-1 | RPAR | RPARPAR | Tumor penetration | | GPCR (GLP-1R) | GLP-1 analogs | various | Metabolic targeting | | Cell-penetrating | TAT (YGRKKRRQRRR) | TAT 11-mer | CNS delivery | | Mitochondrial | SS-31 | D-Arg-Dmt-Lys-Phe-NH2 | Cardiac targeting | | Tumor MT1-MMP | Bicyclic peptide | various | Solid tumors |

2. Linker chemistry

The linker connects peptide to payload and determines release mechanism:

Cleavable linkers:

• **Valine-citrulline-PABC**: cathepsin B-cleavable, the most common cleavable linker in PDCs and ADCs
• **Hydrazone**: acid-cleavable (lysosomal pH 4.5-5.0)
• **Disulfide**: glutathione-reducible in the cytoplasm
• **Ester**: esterase-cleavable, often used for SN-38 conjugates

Non-cleavable linkers:

• **Amide bond**: stable in circulation, releases payload only after complete degradation
• **PEG spacer**: adds solubility and circulation time
• **Triazole (click chemistry)**: stable, modular attachment

3. Cytotoxic payload

Common PDC payloads:

| Payload | Mechanism | Common Conjugate | | --- | --- | --- | | DM1 / DM4 | Microtubule inhibitor | Trastuzumab-emtansine analog | | MMAE / MMAF | Microtubule inhibitor | Brentuximab-vedotin analog | | Camptothecin / SN-38 | Topoisomerase I inhibitor | Irinotecan metabolite analog | | Duocarmycin | DNA alkylator | Antibody-cyd conjugate | | Doxorubicin | DNA intercalator | AN-152 analog | | Paclitaxel | Microtubule stabilizer | ANG1005 |

Clinical pipeline: PDCs in oncology

ANG1005 (AngioChem)

• **Target**: LRP-1 (low-density lipoprotein receptor-related protein 1), expressed on blood-brain barrier and tumor cells
• **Peptide**: Angiopep-2 (19 amino acids)
• **Payload**: Paclitaxel (3 molecules per peptide)
• **Indication**: Glioblastoma, brain metastases
• **Status**: Phase 2/3

ANG1005 is the most clinically advanced PDC. The angiopep-2 peptide shuttles paclitaxel across the blood-brain barrier via LRP-1-mediated transcytosis, achieving drug concentrations in brain tumors 10x higher than free paclitaxel.

BT1718 (Bicycle Therapeutics)

• **Target**: MT1-MMP (membrane type 1 matrix metalloproteinase), overexpressed in solid tumors
• **Peptide**: Bicyclic constrained peptide (~1.5 kDa)
• **Payload**: DM1 (microtubule inhibitor)
• **Indication**: Solid tumors expressing MT1-MMP
• **Status**: Phase 1/2

Bicyclic peptides combine the binding affinity of antibodies with the size advantages of small molecules. They are an important emerging class of PDC targeting ligands.

CBO-P11 (CytomX)

• **Target**: CD166 (activated in tumor microenvironment)
• **Peptide**: Probody-based, masked targeting ligand
• **Payload**: MMAE
• **Indication**: Solid tumors
• **Status**: Phase 1

Probodies use protease-activatable masks that are cleaved in the tumor microenvironment, reducing off-target toxicity.

CBX-12 (Cybrexa Therapeutics)

• **Target**: Tumor micro-environment (pH-dependent uptake)
• **Peptide**: pH-low insertion peptide (pHLIP)
• **Payload**: Exatecan (topoisomerase I inhibitor)
• **Indication**: Solid tumors
• **Status**: Phase 1/2

pHLIP peptides insert into cell membranes only at low pH (6.0-6.5), which is characteristic of tumor microenvironments. This creates selective uptake in tumors.

Peptide engineering for PDC applications

Cyclization

Linear peptides are rapidly degraded by proteases. Cyclization (head-to-tail, side-chain-to-side-chain, or backbone cyclization) increases:

• Proteolytic stability (10-100x)
• Receptor binding affinity
• Plasma half-life

Common cyclization strategies:

• Disulfide bridge (between two Cys residues)
• Lactam bridge (between Asp/Glu and Lys side chains)
• Click chemistry (between azide and alkyne)
• Head-to-tail amide bond

Stapled peptides

Stapled peptides incorporate a hydrocarbon staple between two α-methylated residues (typically at i, i+4 or i, i+7 positions). The staple:

• Locks the peptide in an α-helical conformation
• Increases binding affinity for target proteins (often MDM2, BCL-2)
• Improves cell permeability
• Resists proteolytic degradation

Cell-penetrating peptides (CPPs)

CPPs enable intracellular delivery of conjugated cargoes:

| CPP | Sequence | Origin | | --- | --- | --- | | TAT | YGRKKRRQRRR | HIV-1 transactivator | | Penetratin | RQIKIWFQNRRMKWKK | Antennapedia homeodomain | | R8 (octaarginine) | RRRRRRRR | Polyarginine | | Transportan | GWTLNSAGYLLGKINLKALAALAKKIL | Chimeric | | Arg9 | nona-arginine | Synthetic |

CPP-PDCs enable delivery of cytotoxic payloads that don't normally cross cell membranes, expanding the druggable target space.

Quality control for PDC research

PDC synthesis requires rigorous analytical characterization:

HPLC purity: Target ≥95% for in vitro studies, ≥98% for in vivo studies. The conjugate peak must be well-separated from free peptide and free payload peaks.

Mass spectrometry: ESI-MS or MALDI-MS confirms:

• Correct peptide mass
• Correct linker mass
• Correct payload mass
• Expected total conjugate mass

Drug-to-peptide ratio (DAR): UV spectroscopy at 280 nm and payload-specific wavelengths determines the average number of payload molecules per peptide.

Linker integrity: Stability studies under physiological conditions (PBS pH 7.4, 37°C) confirm that the linker is stable in circulation but cleavable in the target compartment.

Aggregation state: Size-exclusion chromatography confirms the PDC is monomeric and not aggregated.

Research applications and future directions

PDCs are expanding beyond oncology:

• **CNS delivery**: ANG1005 demonstrates brain-penetrant PDC feasibility
• **Cardiovascular**: SS-31 conjugates targeting mitochondria
• **Metabolic diseases**: GLP-1-PDCs targeting metabolic tissues
• **Anti-inflammatory**: RGD-targeted dexamethasone conjugates
• **Antimicrobial**: cationic peptide-tobramycin conjugates for resistant infections

Summary

Peptide-drug conjugates are an emerging therapeutic modality that combines the targeting specificity of biologics with the manufacturing simplicity of small molecules. With several candidates in clinical trials and growing research interest, PDCs represent a major opportunity for peptide chemistry, drug delivery, and precision medicine.

For research laboratories, custom PDC synthesis with validated linker chemistry, complete analytical characterization, and reliable supply enables both basic research and translational studies.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.